Open-label phase i trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

Investigational New Drugs

Volumn 27, Issue 3, 2009, Pages 253-261

  Michael, Michael ^a   Gibbs, Peter ^b   Smith, Robert ^c   Godwood, Alex ^c   Oliver, Stuart ^c   Tebbutt, Niall ^d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ASTRAZENECA   (United Kingdom)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

Colorectal cancer; EGFR; MFOLFOX6; Phase I; Vandetanib; VEGFR

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; VANDETANIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOKALEMIA; HYPONATREMIA; LETHARGY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PIPERIDINES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 64649096230     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9182-8     Document Type: Article

References (32)

1. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676
2. JC Lee NH Chow ST Wang SM Huang 2000 Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients Eur J Cancer 36 748 753
3. T Tokunaga Y Oshika Y Abe 1998 Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer Br J Cancer 77 998 1002
4. H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342
5. LB Saltz S Clarke E Diaz-Rubio 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019
6. A Mayer M Takimoto E Fritz 1993 The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer Cancer 71 2454 2460
7. J Tabernero E Van Cutsem E Diaz-Rubio 2007 Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 5225 5232
8. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345
9. E Van Cutsem M Nowacki I Lang 2007 Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial J Clin Oncol 25 185 4000
10. LB Saltz HJ Lenz HL Kindler 2007 Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 4557 4561
11. Punt CJ, Tol J, Rodenburg CJ et al (2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(15S):LBA4011
12. Hecht JR, Mitchell E, Chidiac T et al (2008) An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). American Soc Clin Oncol GI Cancers Symposium: abst 273
13. SR Wedge DJ Ogilvie M Dukes 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655
14. M Ichihara Y Murakumo M Takahashi 2004 RET and neuroendocrine tumors Cancer Lett 204 197 211
15. SN Holden SG Eckhardt R Basser 2005 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 1391 1397
16. T Tamura H Minami Y Yamada 2006 A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors J Thorac Oncol 1 1002 1009
17. Natale RB, Bodkin D, Govindan R et al (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized Phase II trial. J Clin Oncol 24(18S):abst 7000
18. JV Heymach BE Johnson D Prager 2007 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 4270 4277
19. Heymach J, Paz-Ares L, de Braud F et al (2007) Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S):abst 7544
20. P Therasse SG Arbuck EA Eisenhauer 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
21. S Cascinu R Berardi S Salvagni 2008 A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation Br J Cancer 98 71 76
22. WA Messersmith DA Laheru NN Senzer 2004 Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities Clin Cancer Res 10 6522 6527
23. BM Wolpin JW Clark JA Meyerhardt 2006 Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer Clin Colorectal Cancer 6 208 213
24. S Giacchetti B Perpoint R Zidani 2000 Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 136 147
25. Chen E, Jonker D, Maclean M et al (2006) Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group. EJC Supplements 4(12):abst 93
26. BJ Giantonio PJ Catalano NJ Meropol 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544
27. AL Thomas T Trarbach C Bartel 2007 A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer Ann Oncol 18 782 788
28. MA Graham GF Lockwood D Greenslade 2000 Clinical pharmacokinetics of oxaliplatin: a critical review Clin Cancer Res 6 1205 1218
29. CH Takimoto LK Yee DJ Venzon 1999 High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion Clin Cancer Res 5 1347 1352
30. H Izzedine O Rixe B Billemont 2007 Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension Am J Kidney Dis 50 203 218
31. Abhyankar VV, Sharma S, Trowbridge RC et al (2008) Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A phase I study. J Clin Oncol 26(15S):abst 4112
32. P Kupsch BF Henning K Passarge 2005 Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer Clin Colorectal Cancer 5 188 196